A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found a connection between RNA and SLE.
The study included 90 participants – 60 people with SLE who were split into two groups (30 with LN and 30 without LN) along with 30 healthy controls. All participants shared a comprehensive health history, underwent a clinical examination, and underwent serum sample collection and routine laboratory tests; those with LN had renal biopsies performed. Researchers found IncRNA CASC2 levels were increased in people with SLE compared to the controls, and even higher levels in those with LN. miR-155 levels were down-regulated in people with SLE relative to the control, and especially lower in the LN group. Both elevated IncRNA CASC2 and reduced miR-155 levels were linked to lupus disease severity.
The findings highlight the potential for these two biomarkers as valuable non-invasive indicators for diagnosing SLE, predicting LN among people with SLE, and assessing disease severity and progression. Future studies with more participants are needed to validate findings. Learn more about diagnosing lupus.
This post was originally published on this site